1. Home
  2. EPRX
  3. EPRX News

Latest EUPRAXIA PHARMACEUTICALS INC (EPRX) News on November 17, 2024

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
EPRX

CNW Group

3 days ago

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
EPRX

PR Newswire

3 days ago

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
EPRX

PR Newswire

4 days ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
EPRX

CNW Group

5 days ago

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
EPRX

PR Newswire

10 days ago

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
EPRX

PR Newswire

17 days ago

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
EPRX

CNW Group

21 days ago

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
EPRX

PR Newswire

a month ago

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
EPRX

CNW Group

a month ago

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
EPRX

CNW Group

a month ago

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
EPRX

PR Newswire

a month ago

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Eupraxia Pharmaceuticals Strengthens Senior Management Team
EPRX

PR Newswire

2 months ago

Eupraxia Pharmaceuticals Strengthens Senior Management Team

Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
EPRX

PR Newswire

2 months ago

Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases

Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
EPRX

CNW Group

2 months ago

Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
EPRX

CNW Group

2 months ago

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
EPRX

PR Newswire

3 months ago

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
EPRX

CNW Group

3 months ago

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
EPRX

CNW Group

4 months ago

Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
EPRX

PR Newswire

4 months ago

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
EPRX

CNW Group

4 months ago

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
EPRX

CNW Group

4 months ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
EPRX

GuruFocus.com

5 months ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

EPRX

Energy Global

5 months ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
EPRX

USA TODAY

5 months ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
EPRX

Business Wire

5 months ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
EPRX

Business Wire

5 months ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

SEALSQ to Launch Two New Quantum Resistant Chips
EPRX

GlobeNewswire

5 months ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll
EPRX

Reuters

5 months ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030
EPRX

GlobeNewswire

5 months ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
EPRX

PR Newswire

5 months ago

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
EPRX

PR Newswire

5 months ago

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
EPRX

CNW Group

6 months ago

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
EPRX

PR Newswire

6 months ago

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
EPRX

PR Newswire

6 months ago

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
EPRX

CNW Group

6 months ago

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
EPRX

PR Newswire

6 months ago

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
EPRX

CNW Group

6 months ago

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
EPRX

CNW Group

7 months ago

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
EPRX

CNW Group

7 months ago

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
EPRX

PR Newswire

7 months ago

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

Share on Social Networks: